CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 72 enrolled
Drug / intervention
Toxoplasmosis serology +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02843438
NCT02843438N/ACompleted

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

University Hospital, Grenoble·interventional·Posted Jul 25, 2016·Updated Jul 25, 2016

In Brief

A clinical study evaluating Fluorescein angiography, Dilated fundus examination, and 4 other interventions for Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection. Completed, enrolled 72 participants across 1 site.

Detailed Summary

Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful. Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans. The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis. The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2016
Enrollment StartJan 1, 2010
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 9.9 years ago

Interventions

Fluorescein angiographyother

Dilated fundus examinationother

Toxoplasmosis serologybiological

Anti-toxoplasmosis treatmentdrug

Anti-inflammatory treatmentsdrug

Puncture in anterior chamberother